Literature DB >> 23185149

Hepatocellular adenomas associated with hepatic granulomas: experience in five cases.

Matthanja Bieze1, Paulette Bioulac-Sage, Joanne Verheij, Charles Balabaud, Christophe Laurent, Thomas M van Gulik.   

Abstract

We present five cases in whom two rare entities were simultaneously found within the liver, i.e. hepatocellular adenomas (HCAs) and granulomas. Coexistence of both entities confuses diagnosis. Our aim is to disclose the association between HCA and hepatic granulomas. Five patients presented with HCA for which they underwent resection. During laparotomy or at pathological examination, granulomas were found in tumorous and non-tumorous tissue. No specific cause for the granulomas was found. Immunohistochemistry showed overexpression of C-reactive protein and serum amyloid A in 4/5 patients, classifying these lesions as inflammatory HCA. HCA and especially the inflammatory subtype may cause formation of granulomas in (peri-)tumorous tissue as a local response to persistent inflammation and/or the presence of a tumor. Both HCA and hepatic granulomas have also been associated with oral contraceptive use. In conclusion, HCAs associated with hepatic granulomas derive from a local response to (inflammatory) HCA or neoplasm, chronic use of oral contraceptives, or a combination of these factors.

Entities:  

Keywords:  Benign; Hepatic granuloma; Hepatocellular adenoma; Inflammation; Liver; Oral contraceptives

Year:  2012        PMID: 23185149      PMCID: PMC3506110          DOI: 10.1159/000343434

Source DB:  PubMed          Journal:  Case Rep Gastroenterol        ISSN: 1662-0631


Introduction

The presence of multiple atypical hepatic lesions in combination with hepatocellular adenoma (HCA) confuses diagnosis when found on imaging or at laparotomy. HCA is a benign hepatic lesion occurring predominantly in young and middle-aged women [1]. Large HCA holds a risk of bleeding (30%) and malignant transformation (4.3%). Because of these risks, lesions >5 cm are generally resected. Molecular histopathological analysis categorizes HCA according to mutations within the lesions, each with a corresponding immunohistochemical phenotype [2]. Hepatic granulomas hold a wide variety of possible causes, although often a precise cause cannot be obtained [3]. Granulomas form in response to chronic exogenous or endogenous antigen presentation and may also form as a local response to specific agents or neoplasm [4]. Common causes of hepatic granulomas include sarcoidosis, tuberculosis, primary biliary cirrhosis, viral or bacterial hepatitis, parasites and drugs. In this paper we present five cases of HCA in whom granulomas in the tumor and/or surrounding liver parenchyma were found, and in 1 case even diffuse granulomatous hepatitis (GH). Three papers in the English literature and one in the French literature have reported the coexistence of HCA and liver granulomas in the past 30 years [5, 6, 7]. Patient characteristics are summarized in table (upper part). Case 3 has been previously published [5]. An overview of previously published cases is shown in the lower part of table 1.
Table 1

Summary of patient and lesion characteristics

ReferenceAge, yearsSexDMBMIOC, yearsHCA, nHCA locationHCA subtypeLocation of hepatic granulomasCharacteristics of hepatic granulomas
This report (case 1)36fII27157diffuseunclassifieddiffuseepithelioid, necrotizing; multinucleated giant cells; diffuse hilar lymphadenopathy
This report (case 2)29fI3110>10diffuseIHCAborder T and NTepithelioid; non-caseating
This report (case 3)*52fII27186diffuseIHCATepithelioid; non-caseating; multinucleated giant cells
This report (case 4)39fII28234rightIHCAT
This report (case 5)32mINA1leftIHCAborder T and NTepithelioid
Martin-Blondel et al., 2010 [7]39fdiffuseepithelioid; non-necrotizing
Neuberger et al., 1980 [15]28f5/91T
Malatjalian and Graham, 1982 [10]31f71leftborder T and NTepithelioid; non-caseating; multinucleated giant cells
Le Bail et al., 1992 [5]39f121IVdiffuse
Grazi et al., 2007 [6]26f102III & IV–Vdiffusemultinucleated giant cells; diffuse hilar lymphadenopathy

Patient characteristics include: age; sex; diabetes mellitus (DM type I or II); body mass index (BMI); years of oral contraceptive use (OC). Lesion characteristics include: number and location of HCA within the liver; subtype of HCA – inflammatory (IHCA) and unclassified; location of hepatic granulomas (diffuse throughout the liver and lesion – within the tumor (T) – border area of tumoral (T) to normal (N) parenchyma); characteristics of HG. *Previously reported [5].

Case 1

A 36-year-old woman with a history of diabetes mellitus (DM) and 15 years of oral contraceptive (OC) use was referred to the surgical department. She presented with acute upper abdominal pain caused by bleeding of a hepatic lesion (12.5 cm) during the 19th week of pregnancy, which was treated by selective arterial embolization of the branches of the feeding hepatic arteries in segment 2 and 3 (fig. ). One year later, the patient presented with abdominal pain similar to the pain during the previous episode of bleeding, and imaging showed signs of recurrent bleeding (fig. 1b). At laparotomy the liver surface appeared macroscopically inhomogeneous with disseminated pale lesions of approximately 0.5–1.0 cm with a tendency to confluence (fig. 1c, d). A diffusely metastasized malignancy was suspected, however intraoperative frozen sections of these lesions revealed granulomas. Histopathological examination showed multiple HCAs: hepatocellular proliferation without cytonuclear atypia, but with the presence of thick-walled vessels, areas of necrosis, hemorrhage, and in some vessels embolization material (fig. 1e). These HCAs remained unclassified as liver fatty acid binding protein (LFABP), glutamine synthetase (GS), C-reactive protein (CRP) and serum amyloid A (SAA) did not show any aberrant expression patterns [8]. Throughout the HCA lesions and liver, tissue was disrupted by epithelioid granulomas with a necrotic center containing multinucleated giant cells (fig. 1f). Ziehl-Neelsen, PAS and Grocott staining were negative. At the outpatient clinic no evidence of sarcoidosis, bacterial or fungal infection was found. Three months after surgery, the patient had fully recovered and resumed work.
Fig. 1

Case 1: imaging and histopathology. a MR image of a 36-year-old woman who presented with acute abdominal pain. The transverse T1-weighted fat-suppressed image shows a lesion in the left liver (A) with hypodense areas consistent with bleeding (arrow). Furthermore, multiple hyperintense lesions compared to the surrounding liver parenchyma are shown (arrowheads). b CT image of the same patient 1 year after the bleeding when she presented with recurrent upper abdominal pain. The transverse image of the arterial phase shows the shrunken lesion in the left liver (A), with a new hypodense area consistent with recent bleeding. Based on the symptoms of upper abdominal pain and the signs of bleeding on imaging, the patient was advised to undergo resection of the lesion. c Macroscopic appearance of the liver at laparotomy, revealing an inhomogeneous liver surface, disseminated pale lesions of approximately 1.0 cm with a tendency to confluence, and a large well-circumscribed lesion in the left liver lobe (arrow). d Intraoperative ultrasound shows the HCA lesion (arrow) and multiple, atypical, small hypodense lesions throughout the liver (arrowheads). e Microscopic appearance of the resected HCA in the left liver lobe. This specimen shows the benign hepatocellular proliferation growing in sheets of cords, without pseudoglandular growth patterns. Solitary arteries (arrow) are seen and portal tracks are lacking (hematoxylin-eosin, 4×). f Microscopic appearance of the surrounding liver parenchyma with a granuloma containing multinucleated giant cells (arrow) (hematoxylin-eosin, 10×).

Case 2

A 29-year-old woman was referred to the surgical department. Patient history included 10 years of OC use, DM type I with diabetic nephropathy (creatine 147 μmol/l; normal 90 μmol/l), and severe hypertension (up to 220/100 mm Hg) which caused encephalopathy (table 1). A contrast-enhanced MRI to evaluate her renal status incidentally showed multiple hepatic lesions <2 cm, one lesion of 5 cm in the left liver, and one lesion in segment 6 of 4.2 cm (fig. ). Preoperative liver biopsy confirmed the diagnosis of HCA and showed hepatic granulomas in the biopsy specimen. The left-lateral segments of the liver were resected and local excision of the lesion in segment 6 was performed. The lesions were consistent with inflammatory HCA, with hemorrhagic changes, sinusoidal dilatation, influx of inflammatory cells and irregular, thick blood vessels. Immunohistochemical staining showed overexpression of CRP and SAA. Beta-catenin, GS and LFABP expression were not aberrant. Within the HCA lesions and at the border of tumorous and non-tumorous tissue, an influx of epithelioid granulomas was found. There were no signs of sarcoidosis or opportunistic infections, and Ziehl-Neelsen and PAS staining were negative. No peri- or postoperative complications occurred and the patient could be discharged on day 7. Six months after surgery the patient was in good condition.

Case 3

A 52-year-old woman with a history of type II diabetes was referred to the liver surgical department for resection of multiple hepatic lesions, as previously reported [5]. The patient had had three normal pregnancies after which she had taken OC for 18 years. In a period of 6 years, the tumor in segments 6/7 enlarged from 2 cm to 7 cm. Ultrasound showed 5 additional smaller nodules measuring 2–3 cm: 4 in the right liver and 1 in segment 2. A right hepatectomy and enucleation of the lesion in segment 2 was performed. All 6 lesions had the same histopathological characteristics consistent with inflammatory HCA. Immunohistochemical staining revealed an overexpression of SAA and CRP, without abnormalities for LFABP, GS and beta-catenin staining. In addition, there were numerous non-necrotizing granulomas inside all tumors which were not present in the non-tumoral liver. The granulomas were composed of lymphocytes, epithelioid cells and multinucleated giant cells, occasionally containing asteroid bodies. There was no argument for opportunistic infections and the following stainings were negative: Ziehl-Neelsen, PAS, Grocott and Warthin-Starry. The non-tumoral liver parenchyma was normal.

Case 4

This 39-year-old woman was referred for resection of a 7 cm hepatic lesion in the right liver lobe discovered by hepatic ultrasound that was carried out for evaluation of elevated serum γGT (360 U/l; normal <40 U/l). Patient history revealed three normal pregnancies, one miscarriage and one abortion, OC use during 23 years, and DM type II. MRI showed a large subcapsular tumor with central necrosis in the right liver, and 2 hemangiomas in the left lobe. A right hemihepatectomy was performed. On histopathological examination a benign hepatocellular proliferation with necrotic and hemorrhagic changes was found, consistent with HCA. Three small nodules were discovered at some distance from the larger tumor, measuring between 1 and 2 cm. All lesions showed typical features of inflammatory HCA by standard microscopy, confirmed by additional immunohistochemistry with overexpression of SAA and CRP, whereas LFABP, GS and beta-catenin were normally expressed. In addition, small epithelioid granulomas were observed within the tumor mixed with inflammatory infiltrates. The non-tumoral liver was mildly steatotic without granulomas.

Case 5

A 32-year-old man with DM type I was admitted to the liver surgical department after discovery by ultrasound of a 10 cm lesion in the left liver lobe. Serum alpha-fetoprotein was normal (<7 U/l) and there were no indications for primary or secondary malignant disease on additional imaging. A left hemihepatectomy was performed. The tumor, bulging from the posterior side of segment 3 of the liver, was well circumscribed and presented with congestive and hemorrhagic areas. In addition to a typical aspect of inflammatory HCA, there were numerous large epithelioid granulomas dispersed inside the tumor and in the immediate peritumoral parenchyma. The non-tumoral liver at distance was normal, except for many glycogenated nuclei. Immunohistochemical staining showed an overexpression of SAA and CRP inside the tumor, confirming inflammatory HCA. Follow-up after resection was uneventful.

Discussion

The presented cases share many similarities, and we therefore propose three possible correlations between HCA and the formation of granulomas. First of all, the chronic inflammatory stress caused by inflammatory HCA might trigger granuloma formation. Inflammatory HCA is more often seen in patients with DM and obesity, and is the most frequent subtype with an incidence of 55–60% [9]; all our cases had a history of DM with a BMI ≥27. The hepatic lesions of 4/5 patients were histologically confirmed to be typical inflammatory HCA [1]. The chronic irritation and inflammatory stress caused by (inflammatory) HCA may cause activation of a cascade of inflammatory mediators and result in the formation of granulomas. This was also suggested by Martin-Blondel et al. [7] in their case study of GH and HCA. After resection of HCA the stressor theoretically subsides, which will subsequently result in the disappearance of the granulomas. This was reported in the case of Malatjalian and Graham [10] where a liver biopsy of the remnant liver was performed 6.5 years after resection of the HCA, revealing no evidence of granulomas anymore. However, no report was made about imaging findings and the biopsy was a single specimen, limiting the conclusion drawn from this investigation. Second, a known cause of hepatic granulomas is the presence of a neoplasm, e.g. Hodgkin's disease or hepatocellular carcinoma [11, 12]. Although HCA is a benign lesion, the liver is likely to respond in a same manner to the presence of the abnormal tumoral tissue. Finally, chronic OC use might also be an underlying etiological factor in both HCA and hepatic granulomas. OCs are listed as one of many drugs known to cause GH [5, 13]. This drug is also associated with growth and development of HCA [13, 14]. Therefore chronic OC use may be a common etiological factor in the formation of HCA and hepatic granulomas in our female patients. The first case presented with multiple HCAs and diffuse granulomatous infiltration in both the existing HCA and the entire liver. This case was not an inflammatory HCA, but remained unclassified. The extensive GH likely reflects a systemic cause. All previously reported cases in literature (table 1) presented with a history of chronic OC use. Interestingly, in the patient described by Neuberger et al. [15] in whom a GH was diagnosed in association with OC use, the liver biopsy performed 6 months after discontinuation of OC revealed no granulomas, which supports this hypothesis. In conclusion, little has been reported on hepatic granulomas in association with HCA. We found, along with HCA, granulomas in (peri)tumorous tissue, but also diffusely infiltrated in the entire liver. We propose that the hepatic granulomas in these cases are a response to persistent inflammation caused by (inflammatory) HCA, a local reaction to a neoplasm, chronic use of OCs, or a combination of these factors.

Disclosure Statement

The authors have no conflicts of interest to declare. No grant or financial support contributed to this paper.
  15 in total

Review 1.  Hepatic neoplasms associated with contraceptive and anabolic steroids.

Authors:  K G Ishak
Journal:  Recent Results Cancer Res       Date:  1979

2.  Granulomatous hepatitis. A review of 50 cases.

Authors:  S H Mir-Madjlessi; R G Farmer; W A Hawk
Journal:  Am J Gastroenterol       Date:  1973-08       Impact factor: 10.864

3.  Oral-contraceptive-associated liver tumours: occurrence of malignancy and difficulties in diagnosis.

Authors:  J Neuberger; B Portmann; H B Nunnerley; J W Laws; M Davis; R Williams
Journal:  Lancet       Date:  1980-02-09       Impact factor: 79.321

4.  Validation of a liver adenoma classification system in a tertiary referral centre: implications for clinical practice.

Authors:  Susanna M van Aalten; Joanne Verheij; Turkan Terkivatan; Roy S Dwarkasing; Robert A de Man; Jan N M Ijzermans
Journal:  J Hepatol       Date:  2010-11-24       Impact factor: 25.083

Review 5.  Granulomas in the liver.

Authors:  David E Kleiner
Journal:  Semin Diagn Pathol       Date:  2006 Aug-Nov       Impact factor: 3.464

6.  Epidemiology of hepatocellular adenoma. The role of oral contraceptive use.

Authors:  J B Rooks; H W Ory; K G Ishak; L T Strauss; J R Greenspan; A P Hill; C W Tyler
Journal:  JAMA       Date:  1979-08-17       Impact factor: 56.272

7.  Liver adenomatosis with granulomas in two patients on long-term oral contraceptives.

Authors:  B Le Bail; H Jouhanole; Y Deugnier; G Salame; J L Pellegrin; J Saric; C Balabaud; P Bioulac-Sage
Journal:  Am J Surg Pathol       Date:  1992-10       Impact factor: 6.394

Review 8.  Genotype phenotype classification of hepatocellular adenoma.

Authors:  Paulette Bioulac-Sage; Jean Frédéric Blanc; Sandra Rebouissou; Charles Balabaud; Jessica Zucman-Rossi
Journal:  World J Gastroenterol       Date:  2007-05-21       Impact factor: 5.742

9.  Associated benign liver tumors in idiopathic granulomatous hepatitis: A case report.

Authors:  Gian Luca Grazi; Gaetano Vetrone; Giorgio Ercolani; Matteo Cescon; Matteo Ravaioli; Matteo Zanello; Barbara Corti; Antonio Daniele Pinna
Journal:  Hepatol Res       Date:  2007-07       Impact factor: 4.288

10.  Liver adenoma with granulomas. The appearance of granulomas in oral contraceptive-related hepatocellular adenoma and in the surrounding nontumorous liver.

Authors:  D A Malatjalian; C H Graham
Journal:  Arch Pathol Lab Med       Date:  1982-05       Impact factor: 5.534

View more
  1 in total

1.  Pathological Diagnosis of Hepatocellular Cellular Adenoma according to the Clinical Context.

Authors:  Paulette Bioulac-Sage; Christine Sempoux; Laurent Possenti; Nora Frulio; Hervé Laumonier; Christophe Laurent; Laurence Chiche; Jean Frédéric Blanc; Jean Saric; Hervé Trillaud; Brigitte Le Bail; Charles Balabaud
Journal:  Int J Hepatol       Date:  2013-04-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.